Small molecule · Agonist of Adenosine A3 receptor (ADORA3) · developed by Can-Fite BioPharma
Piclidenoson is an orally bioavailable adenosine A3 receptor agonist that binds and activates the G protein-coupled A3 receptor on the cell surface. Activation of this receptor inhibits NF-kB signaling and the production of inflammatory cytokines such as TNF and several interleukins. It is studied in plaque psoriasis, keratoconjunctivitis sicca and rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06643260 | Phase 3 | Plaque Psoriasis | Not yet recruiting | CANF |
| NCT03168256 | Phase 3 | Plaque Psoriasis | Completed | CANF |
| NCT02647762 | Phase 3 | Rheumatoid Arthritis | Terminated | CANF |
| NCT01235234 | Phase 3 | Keratoconjunctivitis Sicca | Completed | CANF |
| NCT00428974 | Phase 2 | Plaque Psoriasis | Completed | CANF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Keratoconjunctivitis SiccaPlaque PsoriasisRheumatoid Arthritis
Updated Oct 11, 2026. Something wrong or missing? Report it on the CANF page.
See CANF's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CANF catalysts and pipeline →